Avastin (Colorectal Cancer) - Forecast and Market Analysis to 2023

Publisher Name :
Date: 28-Nov-2014
No. of pages: 57

GlobalData has released its new PharmaPoint Drug Evaluation report, "Avastin (Colorectal Cancer) Forecast and Market Analysis to 2023". Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Avastin (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Avastin and Vectibix are not recommended.

Avastin was the first agent of a new class of drugs that targeted the angiogenesis pathway. The anti-angiogenic agent is a humanized monoclonal IgG1 that binds to vascular endothelial growth factor-A (VEGF-A), preventing the ligand from binding to the VEGF receptor. Inhibition of the VEGF pathway prevents endothelial cells from proliferating and forming the new bloods vessels that are required for the tumor to grow. The drug delivered as a monotherapy is not curative, and must be co-administered with a chemotherapy regimen.

Scope


  • Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

  • Detailed information on Avastin including product description, safety and efficacy profiles as well as a SWOT analysis.

  • Sales forecast for Avastin for the top eight countries from 2013 to 2023.

  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.


Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return

  • Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer

  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

  • Make more informed business decisions from insightful and in-depth analysis of Avastin performance

  • Obtain sales forecast for Avastin from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

Avastin (Colorectal Cancer) - Forecast and Market Analysis to 2023

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10

3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 13
3.2 Clinical Staging 14
3.3 Symptoms 16

4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
4.1.1 Screening and Diagnosis 17
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 20
4.1.3 Clinical Practice 24

5 Competitive Assessment 31
5.1 Overview 31

6 Avastin (Bevacizumab) 33
6.1 Overview 33
6.2 Efficacy 35
6.3 Safety 35
6.4 SWOT Analysis 37
6.5 Forecast 37

7 Appendix 39
7.1 Bibliography 39
7.2 Abbreviations 45
7.3 Methodology 48
7.4 Forecasting Methodology 48
7.4.1 Diagnosed Colorectal Cancer Patients 48
7.4.2 Percent Drug-Treated Patients 49
7.4.3 General Pricing Assumptions 49
7.4.4 Average Body Weight and Surface Area Across the 8MM 50
7.4.5 Individual Drug Assumptions 50
7.4.6 Generic Erosion 51
7.5 Primary Research - KOLs Interviewed for this Report 52
7.6 Primary Research - Prescriber Survey 53
7.7 About the Authors 54
7.7.1 Analyst 54
7.7.2 Global Head of Healthcare 55
7.8 About GlobalData 56
7.9 Disclaimer 56

List of Tables

Table 1: TNM and Staging Classification System for CRC 15
Table 2: Symptoms of Colorectal Cancer 16
Table 3: Treatment Guidelines for CRC 21
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013 22
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013 23
Table 6: Leading Treatments for CRC, 2014 32
Table 7: Product Profile ? Avastin 34
Table 8: Avastin SWOT Analysis, 2014 37
Table 9: Global Sales Forecast ($m) for Avastin, 2013-2023 38
Table 10: Average Body Weight and Surface Area Across the 8MM 50
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 53

  • Global Small Cell Lung Cancer Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 20-Sep-2018        Price: US 3480 Onwards        Pages: 137
    Lung cancer can be categorized into two types: non-small cell lung cancer and small cell lung cancer. Small cell lung cancer constitutes roughly 10-15 percent of all diagnosed cases of lung cancer. Small cell lung cancer is categorized into two types: small cell carcinoma and combined small cell carcinoma. It can be further classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer. Small cell lung cancer is caused by smoking tobacco, or second ha......
  • Global Ovarian Cancer Therapeutics Market Size, Status and Forecast 2018-2025
    Published: 17-Sep-2018        Price: US 3900 Onwards        Pages: 98
    This report focuses on the global Ovarian Cancer Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Ovarian Cancer Therapeutics development in United States, Europe and China. Ovarian cancer, and its rising incidence rate, is a growing concern worldwide. Market players that are currently engaged in the development of drugs and therapies for ovarian cancer stand to benefit by observing the latest trends and ......
  • Global Non-Melanoma Skin Cancer Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 17-Sep-2018        Price: US 3480 Onwards        Pages: 139
    Non-melanoma skin cancer is usually treated as a simple lesion in the initial stages but if not treated properly, it can quickly mushroom and spread to other body parts. Scope of the Report: This report studies the Non-Melanoma Skin Cancer market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Non-Melanoma Skin Cancer market by p......
  • Global Non-Melanoma Skin Cancer Market Size, Status and Forecast 2018-2025
    Published: 12-Sep-2018        Price: US 3900 Onwards        Pages: 108
    This report focuses on the global Non-Melanoma Skin Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Non-Melanoma Skin Cancer development in United States, Europe and China. Non-melanoma skin cancer is usually treated as a simple lesion in the initial stages but if not treated properly, it can quickly mushroom and spread to other body parts. Radiation therapy has a market share approaching 88% in the non......
  • 2018-2023 Global Bladder Cancer Therapeutics Market Report (Status and Outlook)
    Published: 10-Sep-2018        Price: US 4660 Onwards        Pages: 119
    In this report, LP Information studies the present scenario (with the base year being 2017) and the growth prospects of global Bladder Cancer Therapeutics market for 2018-2023. The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the innermost lay......
  • 2018-2023 Global Breast Cancer Monoclonal Antibodies Market Report (Status and Outlook)
    Published: 10-Sep-2018        Price: US 4660 Onwards        Pages: 155
    In this report, LP Information studies the present scenario (with the base year being 2017) and the growth prospects of global Breast Cancer Monoclonal Antibodies market for 2018-2023. Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protei......
  • Global Circulating Tumor Cells Market by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 10-Sep-2018        Price: US 3480 Onwards        Pages: 152
    Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy. Scope of the Report: This report studies the Circulating Tumor Cells market status and outlook of Global and major regions, from angles of playe......
  • Global Melanoma Partnering 2012 to 2018
    Published: 01-Sep-2018        Price: US 1995 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." The Global Melanoma Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understanding and ......
  • Global Multiple Myeloma Partnering 2012 to 2018
    Published: 01-Sep-2018        Price: US 1995 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." The Global Multiple Myeloma Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understand......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs